Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year
MWN-AI** Summary
Getinge's Q4 and Full-Year Report for 2025, released on January 27, 2026, highlights the company's achievements in organic growth and robust cash flow, with CEO Mattias Perjos noting a record-breaking fourth quarter and full-year organic growth of 4.9%. The sustained demand for consumables, particularly in ECMO therapy and Acute Care Therapies, significantly contributed to this performance. The Surgical Workflows segment also showed strength, particularly in operating tables, while the Life Science sector, despite more volatility, managed to grow organically for the year.
Despite facing challenges such as tariffs and currency fluctuations exceeding SEK 1 billion, Getinge maintained its adjusted EBITA margin, which remains consistent with the previous year's performance. For Q4, the adjusted EBITA margin was reported at 17.8%, indicating effective cost control and productivity measures. Additionally, Getinge's free cash flow for the year was healthy, amounting to SEK 2.652 billion, although somewhat lower than the previous year.
During the quarter, Getinge introduced notable product innovations, such as Automatiq, an advanced sterile reprocessing automation system that utilizes smart robotics and has already garnered initial orders. The company also made strides in regulatory compliance, with products receiving necessary approvals, enhancing its market competitiveness.
Looking ahead, Getinge anticipates organic sales growth of 3–5% for 2026, supported by stable healthcare needs and hospitals’ readiness to invest. The company proposed a dividend of SEK 4.75 per share, showing a commitment to returning value to shareholders while investing in future growth.
MWN-AI** Analysis
Getinge's Q4 and Full-Year Report for 2025 reveals a company exhibiting resilience amid a challenging market landscape, characterized by organic growth and robust cash flow. The reported 4.9% organic growth for the year, aligning with forecasts, signals a solid performance, particularly in the Acute Care and Transplant Care segments. The elevated order bookings for Surgical Workflows and strong demand for products like ventilators present a promising trajectory as Getinge enters 2026.
However, the report also outlines headwinds arising from tariffs and currency fluctuations, impacting nearly SEK 1 billion of revenue compared to the previous year. Despite this, Getinge maintained its adjusted EBITA margin at 14.0% for the full year, reflecting effective cost control and strategic pricing. This stability in profitability is critical for investor confidence, especially in the healthcare sector, where financial prudence can significantly influence growth prospects.
Furthermore, investments in innovative product lines such as Automatiq—a next-generation reprocessing automation system—demonstrate Getinge's commitment to enhancing operational efficiency and patient safety. These advancements, paired with strong regulatory compliance, position the company favorably against competitors. The upcoming European deliveries of updated products, including the Cardiosave intra-aortic balloon pump, suggest a potential uplift in revenue as market demand grows.
Moving forward, investors should consider Getinge's projected organic sales growth of 3–5% for 2026, despite geopolitical uncertainties. The company’s focus on sustained product development and market demand stability indicates potential for continued long-term growth. An attractive dividend proposal further enhances its investment appeal. Those looking for a resilient stock with a history of adapting to market conditions may find Getinge a compelling choice for their portfolio.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
GOTHENBURG, Sweden, Jan. 27, 2026 /PRNewswire/ -- "We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year," says Mattias Perjos, President & CEO at Getinge.
Higher demand for consumables for ECLS-therapy in the quarter and in Acute Care Therapies contributed to Getinge's performance. Sales were also strong in Transplant Care and ventilators. Surgical Workflows continued to strengthen its market-leading position in operating tables and enters 2026 with robust order bookings. In general, sales are more volatile between quarters for Life Science, which grew organically for the full-year despite the weaker end.
"Despite headwinds from tariffs and currency effects for the full-year 2025 of more than SEK 1 billion compared with last year, we maintained adjusted EBITA margin for the full-year in line with 2024 and deliver a solid cash flow. Excluding effects from currency and tariffs, adjusted EBITA margin was 20.3% in the quarter and 16.0% for the full year, which is considerably higher than last year. This confirms the positive trend in underlying profitability thanks to our sustained focus on price adjustments, productivity and cost control," says Mattias Perjos, President & CEO at Getinge.
Getinge's intensive development efforts have resulted in several important product launches during the quarter.
"One example is Automatiq, the next generation of sterile reprocessing automation systems using smart robotics, which will ultimately lead to safer and more efficient processes. The system is requested by customers, and we have already received the first orders. The ambition is to accelerate development efforts of new products over the coming years which will further strengthen our competitiveness," says Perjos.
Getinge continued to make progress in regulatory compliance. Rotaflow consumables in ECLS received EU MDR approval and the iCast covered stent received PMA for two additional versions, which enhances Getinge's competitiveness in the US.
"European deliveries of our intra-aortic balloon pump Cardiosave, which had its CE certificate reinstated in the fall, are expected to start in the second quarter of 2026. We pushed this date due to a delay in shipment of critical components," Perjos explains and adds that order intake for Cardiosave is strong and that there is clear market demand.
"We demonstrated during the year that we are well positioned in priority product categories. In addition, stable healthcare needs and the continued willingness of hospitals to invest are creating favorable conditions for long-term growth."
There's currently high geopolitical uncertainty however based on underlying demand, Getinge expects organic sales growth of 3–5% in 2026.
"I would like to express my sincere thanks to all our customers and employees for their important 2025 efforts in continuing creating value for clinical staff and patients," says Perjos.
October – December 2025 in brief
- Net sales increased organically by 1.2% (9.2) and the order intake rose by 2.3% organically (7.4)
- Adjusted gross profit amounted to SEK 5,037 M (5,604) and the margin was 49.5% (50.6)
- Adjusted EBITA was SEK 1,809 M (2,143) and the margin 17.8% (19.4)
- Adjusted earnings per share amounted to SEK 4.45 (5.28)
- Free cash flow amounted to SEK 1,190 M (1,693)
January – December 2025 in brief
- Net sales increased organically by 4.9% (4.9) and the order intake rose by 3.5% organically (6.3)
- Adjusted gross profit amounted to SEK 17,607 M (17,409) and the margin was 50.4% (50.1)
- Adjusted EBITA was SEK 4,880 M (4,869) and the margin 14.0% (14.0)
- Adjusted earnings per share amounted to SEK 11.29 (11.73)
- Free cash flow amounted to SEK 2,652 M (3,284)
- A dividend per share of SEK 4.75 (4.60) is proposed
Phone Conference
A conference call will be held on January 27, 2026, at 10:00-11:00 a.m. CET hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.
To participate via teleconference, please register via this link. After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
During the conference call a presentation will be held. To access the presentation through webcast, please use this link. A recorded version can be accessed here for 3 years.
Contact:
David Kördel, Head of Investor Relations
Phone: +46 (0)10 335 0077
Email: david.kordel@getinge.com
This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on January 27, 2026, at 08:00 am CET.
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Getinge - Report Q4 and Full Year 2025 | |
https://mb.cision.com/Public/942/4298077/a27fc58bd65e5db8.pdf | Press Release - Getinge Q4 and Full-Year Report 2025 |
SOURCE Getinge
FAQ**
In light of the reported 4.9% organic growth for 2025, how does Getinge AB ADR GNGBY plan to continue expanding its market share in areas like Acute Care Therapies and ECLS-therapy in 2026?
With a solid cash flow reported and the adjusted EBITA margin maintained at 14.0%, what specific strategies will Getinge AB ADR GNGBY implement to improve profitability amidst the challenges of tariffs and currency effects?
Can you provide insights on how the recent product launches, such as the Automatiq and regulatory approvals for key consumables, will impact the competitive positioning of Getinge AB ADR GNGBY moving into 2026?
Given the geopolitical uncertainties mentioned in the report, how is Getinge AB ADR GNGBY preparing to navigate potential market volatility while still aiming for organic sales growth of 3–5% in 2026?
**MWN-AI FAQ is based on asking OpenAI questions about Getinge AB ADR (OTC: GNGBY).
NASDAQ: GNGBY
GNGBY Trading
2.59% G/L:
$21.25 Last:
3,211 Volume:
$21.49 Open:
